In this medfyle

Treatment with BTKi ibrutinib increases the risk of cardiovascular side effects such as abnormal heart rhythms and high blood pressure. The next-generation BTKi acalabrutinib was developed with improved target selectivity to help reduce off-target adverse events observed with ibrutinib. Updated safety results confirm that acalabrutinib had an improved safety profile with statistically fewer atrial fibrillation events and numerically fewer discontinuations due to adverse events than ibrutinib in patients with relapsed/refractory CLL.